Table 2. Clinical characteristics and laboratory findings of transplant and non-transplant patients with COVID-19.
| Variables | Transplanted n = 41 (%) | Non-transplanted n = 220 (%) | p |
|---|---|---|---|
| Age in years, median (IQR) | 58 (33–86) | 63 (51–72) | 0.175 |
| Male sex | 27 (66) | 144 (66) | 0.961 |
| Underlying conditions | |||
| Hypertension | 33 (81) | 98 (45) | <0.001 |
| Diabetes mellitus | 34 (16) | 13 (32) | 0.013 |
| Cardiovascular disease | 10 (24) | 29 (13) | 0.065 |
| COPD | 8 (20) | 38 (17) | 0.730 |
| Chronic kidney disease | 14 (34) | 11 (5) | < 0.001 |
| Symptoms at admission | |||
| Fever | 39 (95) | 201 (91) | 0.417 |
| Diarrhea | 9 (22) | 48 (22) | 0.985 |
| Dyspnoea | 13 (32) | 126 (57) | 0.003 |
| Cough | 27 (68) | 181 (82) | 0.032 |
| Median days from symptoms to diagnosis (IQR) | 5 (2–9) | 6 (4–8) | 0.276 |
| Laboratory values on admission, median (IQR) | |||
| Lymphocyte (cell/mm) | 600 (400–900) | 800 (600–1000) | 0.220 |
| C-reactive protein (mg/dL) (NR<0) | 9.4 (3–13.8) | 8.1 (4.2–16.8) | 0.479 |
| D- dimer (ng/mL) (NR<500) | 800 (600–2447) | 800 (450–1400) | 0.706 |
| Lactate dehydrogenase (IU/mL) (NR<234) | 289(400–900) | 338 (264–424) | 0.390 |
| Creatinine, (mg/dL) (NR 0.3–1.3) | 1.8 (1.2–2.9) | 0.9 (0.7–1.09) | <0.001 |
| Ferritin (ng /mL) (NR 20–400) | 321 (264–949) | 776 (391–1421) | 0.030 |
| Troponin (ng /mL) (NR <42.2) | 8.2 (4.7–30.7) | 11.2 (5.1–20.5) | 0.551 |
| COVID-19 adjuvant treatment | |||
| Lopinavir/ritonavir | 31 (76) | 205 (93) | 0.001 |
| Hydroxychloroquine | 40 (98) | 216 (98) | 0.390 |
| Azithromycin | 41 (100) | 220 (100) | 0.932 |
| Tocilizumab | 19 (46) | 125 (57) | 0.216 |
| Anakinra | 7 (17) | 4 (2) | <0.001 |
| Baricitinib | 1 (2) | 0 | 0.020 |
| Remdesivir | 0 | 29 (13) | 0.005 |
| Anti-cytokine therapy | 23 (56) | 125 (57) | 0.932 |
| Clinical outcomes | |||
| Intensive care unit admission | 14 (34) | 90 (41) | 0.317 |
| • non-invasive ventilation | 7 (17) | 47 (21) | 0.928 |
| • mechanical ventilation | 7 (17) | 43 (19) | 0.325 |
| Complications | |||
| Acute kidney injury | 20 (49) | 35 (16) | 0.001 |
| Other infection | 10 (24) | 26 (19) | 0.462 |
| Septic shock | 5 (12) | 51 (23) | 0.110 |
| Organizing pneumonia | 4 (10) | 42 (19) | 0.150 |
| Pulmonary embolism | 0 | 21 (10) | 0.04 |
| Higher/lower* laboratory values during admission, median (IQR) | |||
| Lymphocyte (cell/mm) | 700 (500–1100) | 1600 (1200–2300) | 0.001 |
| C-reactive protein (mg/dL) | 14.4 (9–18.9) | 15.5 (8.8–22.6) | 0.754 |
| D-dimer (ng/mL) | 1300 (1000–4010) | 2400 (1000–7600) | 0.190 |
| Lactate dehydrogenase (IU/mL) | 367 (285–525) | 448 (348–567) | 0.027 |
| Ferritin (ng /mL) | 888 (442–1515) | 1135 (648–1934) | 0.161 |
| Troponin (ng/mL) | 15.2 (7.1–52.0) | 13.7 (6.3–31.2) | 0.860 |
| Median days of hospitalization (IQR) | 17 (12–24) | 12 (8–20) | 0.054 |
| Median days in ICU, median (IQR) | 11 (7–22) | 9 (5–15) | 0.303 |
| Mortality | 5 (12.2) | 33 (15) | 0.640 |
* In case of C-reactive protein, D-dimer, lactate dehydrogenase, ferritin and troponin we selected the highest laboratory value during hospitalization. And in case of lymphocyte count we select the lowest laboratory value.